CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Placebo oral tablet +1 moredrug
Likely dose
Letrozole 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04002141
NCT04002141Phase 2Completed
CompareCT.gov

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

University of California, San Francisco·interventional·Posted Jun 28, 2019·Updated Jan 28, 2026

In Brief

A Phase 2 clinical trial evaluating Placebo oral tablet and Letrozole for Endometriosis and Ovarian Hyperstimulation. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Randomized double blinded placebo-controlled trial to evaluate the impact of ovarian hyperstimulation on endometriosis-related symptoms and to evaluate the impact of letrozole use during ovarian hyperstimulation with respect to endometriosis-related symptoms, embryo/egg quality and quantity, and pregnancy rates.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis, Ovarian Hyperstimulation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 28, 2019
Enrollment StartSep 17, 2019
Primary CompletionOct 1, 2023
Study CompletionJan 1, 2025
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.0 years ago

Interventions

Placebo oral tabletdrug

1 tablet oral daily

Letrozoledrug

5mg oral daily